Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Biotech
Atossa Therapeutics Debuts Preliminary Analysis From Innovative Clinical Trial
Atossa Therapeutics (NASDAQ: ATOS) has released new clinical data from their Phase II trial for (Z)-Endoxifen.
November 1, 2024
Biotech
Public Companies
Biotech
Seaport Therapeutics Raises Mega Funding Round For New Antidepressants
PureTech Health (NASDAQ: PRTC) has announced that their founded entity Seaport Therapeutics has raised $225M USD in a Series B financing round.
October 22, 2024
Venture Capital
Biotech
Biotech
Firefly Neuroscience and Bright Minds Biosciences Collaborate On Clinical Trial Data
Firefly Neuroscience (NASDAQ: AIFF) and Bright Mind Biosciences (NASDAQ: DRUG) are collaborating to leverage AI technology for clinical trial data evaluation.
October 16, 2024
Artificial Intelligence
Biotech
Public Companies
Psychedelics
Biotech
There’s A New FDA Approved Drug For Schizophrenia
PureTech Health (NASDAQ: PRTC) has received an official approval from the United States FDA for their novel therapeutic KarXT for schizophrenia treatment.
October 1, 2024
Biotech
Regulatory
Public Companies
Biotech
BioAge Labs Debuts On Nasdaq To Advance Weight Loss Drugs
Clinical stage biopharmaceutical company BioAge Labs (NASDAQ: BIOA) has officially listed on the Nasdaq after successfully raising $198 million in their IPO.
September 27, 2024
Biotech
IPO
Biotech
Elon Musk’s Neuralink Declared Breakthrough Device By FDA
Elon Musk’s brain computer interface company Neuralink has been awarded a Breakthrough Device designation by the United States FDA for their Blindsight device.
September 18, 2024
Biotech
Regulatory
Biotech
The Startup Building Breakthrough Technology To Bio-Manufacture Blood
Pre-clinical blood cell therapy startup Safi Biotherapeutics has raised $5 million in seed funding led by prominent deep tech venture capital fund J2 Ventures.
September 17, 2024
Biotech
Startups
Venture Capital
Biotech
MIRA Pharmaceuticals Wants To Change The Paradigm Of Neuropathic Pain
MIRA Pharmaceuticals (NASDAQ: MIRA) has officially designated neuropathic pain as the initial and primary indication for their novel oral ketamine analogue.
September 11, 2024
Biotech
Public Companies
Discover the world's most disruptive early stage companies with 35,000+ investors.
The markets and trends that matter, made simple.
Join top talent at the world's most respected institutions, companies, and venture capital funds.